These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 29562804)

  • 21. Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.
    Necchi A; Giardiello D; Mariani L
    Eur Urol; 2017 May; 71(5):840-841. PubMed ID: 27720533
    [No Abstract]   [Full Text] [Related]  

  • 22. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
    Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C
    BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The emerging role of immunotherapy in advanced urothelial cancers.
    Tabayoyong W; Gao J
    Curr Opin Oncol; 2018 May; 30(3):172-180. PubMed ID: 29553950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
    Bellmunt J; Powles T; Vogelzang NJ
    Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade.
    Galsky MD
    Nat Rev Urol; 2018 Feb; 15(2):71-72. PubMed ID: 29182606
    [No Abstract]   [Full Text] [Related]  

  • 26. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atezolizumab in urothelial bladder carcinoma.
    Hamilou Z; Lavaud P; Loriot Y
    Future Oncol; 2018 Feb; 14(4):331-341. PubMed ID: 29135284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pembrolizumab as second-line treatment for urothelial cancer.
    Mitchell F
    Lancet Oncol; 2017 Apr; 18(4):e197. PubMed ID: 28238595
    [No Abstract]   [Full Text] [Related]  

  • 29. Pembrolizumab in the treatment of advanced urothelial cancer.
    Lundgren KT; Farina MS; Bellmunt J
    Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer.
    Ullén A
    Acta Oncol; 2019 Jul; 58(7):951-952. PubMed ID: 31232133
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.
    Elias R; Giobbie-Hurder A; McCleary NJ; Ott P; Hodi FS; Rahma O
    J Immunother Cancer; 2018 Apr; 6(1):26. PubMed ID: 29618381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
    Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
    J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
    Chism DD
    J Natl Compr Canc Netw; 2017 Oct; 15(10):1277-1284. PubMed ID: 28982752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Khunger M; Jain P; Rakshit S; Pasupuleti V; Hernandez AV; Stevenson J; Pennell NA; Velcheti V
    Clin Lung Cancer; 2018 May; 19(3):e335-e348. PubMed ID: 29433902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.
    Winer A; Ghatalia P; Bubes N; Anari F; Varshavsky A; Kasireddy V; Liu Y; El-Deiry WS
    Oncologist; 2019 Nov; 24(11):1416-1419. PubMed ID: 31444293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma.
    Balar AV
    Oncology (Williston Park); 2019 Apr; 33(4):132-6. PubMed ID: 30990565
    [No Abstract]   [Full Text] [Related]  

  • 37. Immune checkpoint inhibitors for metastatic bladder cancer.
    Massari F; Di Nunno V; Cubelli M; Santoni M; Fiorentino M; Montironi R; Cheng L; Lopez-Beltran A; Battelli N; Ardizzoni A
    Cancer Treat Rev; 2018 Mar; 64():11-20. PubMed ID: 29407369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
    Bednova O; Leyton JV
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.
    Wu Y; Lin L; Shen Y; Wu H
    Int J Cancer; 2018 Dec; 143(11):3038-3040. PubMed ID: 29987914
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunotherapy and urothelial carcinoma: An overview and future prospectives.
    Pierantoni F; Maruzzo M; Gardi M; Bezzon E; Gardiman MP; Porreca A; Basso U; Zagonel V
    Crit Rev Oncol Hematol; 2019 Nov; 143():46-55. PubMed ID: 31476551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.